News
and Media


Press Releases and Media
November 7, 2023 | Press Release
Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference
– New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) – NEW ORLEANS and CAMBRIDGE, UK, November 7, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that new preclinical …
October 25, 2023 | Press Release
Revolo Biotherapeutics Announces Data from Study of ‘1104 in Atopic Adults
– Treatment with ‘1104 demonstrated a rapid reduction in intradermal allergic inflammation –– Treatment with ‘1104 induced sustained activation of T regulatory and B regulatory cells, providing additional clinical validation of its mechanism of action – NEW ORLEANS and CAMBRIDGE, UK, October 25, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that …
Revolo Biotherapeutics Announces Data from Study of ‘1104 in Atopic Adults Read More »
October 17, 2023 | Press Release
Revolo Biotherapeutics to Present Data from Phase 2a Clinical Trial of ‘1104 in Eosinophilic Esophagitis at ACG 2023
NEW ORLEANS and CAMBRIDGE, UK, October 17, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will present the previously announced Phase 2a trial data evaluating its immune-resetting drug candidate, ‘1104, in …